WO2008091798A3 - Optimized ca9 antibodies and methods of using the same - Google Patents

Optimized ca9 antibodies and methods of using the same Download PDF

Info

Publication number
WO2008091798A3
WO2008091798A3 PCT/US2008/051470 US2008051470W WO2008091798A3 WO 2008091798 A3 WO2008091798 A3 WO 2008091798A3 US 2008051470 W US2008051470 W US 2008051470W WO 2008091798 A3 WO2008091798 A3 WO 2008091798A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
optimized
same
parent antibody
Prior art date
Application number
PCT/US2008/051470
Other languages
French (fr)
Other versions
WO2008091798A2 (en
Inventor
Matthew J Bernett
Wei Dang
John R Desjarlais
Gregory Alan Lazar
Original Assignee
Xencor Inc
Matthew J Bernett
Wei Dang
John R Desjarlais
Gregory Alan Lazar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Matthew J Bernett, Wei Dang, John R Desjarlais, Gregory Alan Lazar filed Critical Xencor Inc
Publication of WO2008091798A2 publication Critical patent/WO2008091798A2/en
Publication of WO2008091798A3 publication Critical patent/WO2008091798A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The present invention describes antibodies that target CA9, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
PCT/US2008/051470 2007-01-22 2008-01-18 Optimized ca9 antibodies and methods of using the same WO2008091798A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88605807P 2007-01-22 2007-01-22
US60/886,058 2007-01-22

Publications (2)

Publication Number Publication Date
WO2008091798A2 WO2008091798A2 (en) 2008-07-31
WO2008091798A3 true WO2008091798A3 (en) 2008-10-02

Family

ID=39580082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051470 WO2008091798A2 (en) 2007-01-22 2008-01-18 Optimized ca9 antibodies and methods of using the same

Country Status (1)

Country Link
WO (1) WO2008091798A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US7632496B2 (en) 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
KR102469853B1 (en) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2576616A4 (en) 2010-05-27 2014-05-21 Merck Sharp & Dohme Method for preparing antibodies having improved properties
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2015035044A2 (en) * 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
PE20221834A1 (en) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd ANTIMYOSTATIN ANTIBODIES
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116251182A (en) 2016-08-05 2023-06-13 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
JP2022524338A (en) * 2019-03-05 2022-05-02 武田薬品工業株式会社 Restrained and conditionally activated binding protein
CN114502596A (en) * 2019-07-02 2022-05-13 泰利克斯国际有限公司 Antibodies to CAIX with reduced affinity for neonatal Fc receptor
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4055055B1 (en) 2020-12-18 2023-11-22 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN113045665B (en) * 2021-03-22 2022-05-13 徐州医科大学 CAIX-CAR-T cell driven by HVEM (high-voltage alternating current) co-stimulation signal as well as preparation method and application of CAIX-CAR-T cell
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies
WO2004017923A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies
WO2004017923A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IVANOV S ET AL: "Expression of hypoxia-inducible cell-surfaces transmembrane carbonic ahydrases in human cancer", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 158, no. 3, 1 March 2001 (2001-03-01), pages 905 - 919, XP002967850, ISSN: 0002-9440 *
NATSUME ET AL: "Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 306, no. 1-2, 30 November 2005 (2005-11-30), pages 93 - 103, XP005197267, ISSN: 0022-1759 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 *
SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258 *
WRIGHT A ET AL: "Effect of glycosylation on antibody function: implications for genetic engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 1, 1 January 1997 (1997-01-01), pages 26 - 32, XP004016809, ISSN: 0167-7799 *

Also Published As

Publication number Publication date
WO2008091798A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008121160A3 (en) Optimized antibodies that target cd5
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2007044616A3 (en) Optimized anti-cd30 antibodies
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009026117A3 (en) Novel compounds
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2007058823A3 (en) Anti-egfr antibodies
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2009112245A9 (en) Antibody against the csf-1 r
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2011091078A3 (en) Antibody fc variants with enhanced complement activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727918

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727918

Country of ref document: EP

Kind code of ref document: A2